<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02755987</url>
  </required_header>
  <id_info>
    <org_study_id>ANG1005-EAP-01, EAP-02, EAP-03</org_study_id>
    <nct_id>NCT02755987</nct_id>
  </id_info>
  <brief_title>Expanded Access to ANG1005 for Individual Patients</brief_title>
  <official_title>Expanded Access to ANG1005 for an Individual Patient With Recurrent WHO Grade III Anaplastic Astrocytoma; Expanded Access to ANG1005 for an Individual Patient With Recurrent WHO Grade III Anaplastic Oligodendroglioma; Expanded Access to ANG1005 for an Individual Breast Cancer Patient With Recurrent Brain Metastases and Leptomeningeal Carcinomatosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Angiochem Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Angiochem Inc</source>
  <brief_summary>
    <textblock>
      This is an expanded access study with ANG1005 treatment for two individual patients from
      Protocol ANG1005-CLN-03 with WHO Grade III Anaplastic Astrocytoma and WHO Grade III
      Anaplastic Oligodendroglioma and one individual patient from Protocol ANG1005-CLN-04 with
      Recurrent Brain Metastases and Leptomeningeal Carcinomatosis.
    </textblock>
  </brief_summary>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <condition>Anaplastic Astrocytoma</condition>
  <condition>Anaplastic Oligodendroglioma</condition>
  <condition>Breast Cancer With Recurrent Brain Metastases</condition>
  <condition>Leptomeningeal Carcinomatosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ANG1005</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Neurologically stable

          2. Karnofsky performance status (KPS) ≥ 80

          3. Adequate laboratory results

        Exclusion Criteria:

          1. Radiotherapy within 3 months.

          2. Evidence of significant intracranial hemorrhage

          3. NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v4.0 Grade ≥ 2 neuropathy

          4. Inadequate bone marrow reserve

          5. Any evidence of severe or uncontrolled disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>UC Irvine Health</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univeristy of Texas Health Science Center in San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2016</study_first_submitted>
  <study_first_submitted_qc>April 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2016</study_first_posted>
  <last_update_submitted>June 3, 2016</last_update_submitted>
  <last_update_submitted_qc>June 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Oligodendroglioma</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Meningeal Carcinomatosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

